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Most patients suffering from psychiatric disorders respond to combinations of psycho- and
psychopharmacotherapy; however there are patients who proﬁt little if anything even after
many years of treatment. Since about a decade different modalities of targeted neuromod-
ulation – among them most prominently – deep brain stimulation (DBS) – are being actively
researched as putative approaches to very treatment-resistant forms of those disorders.
Recently, promising pilot data have been reported both for major depression (MD) and
obsessive–compulsive disorder (OCD). Given the fact that patients included in DBS stud-
ies had been treated unsuccessfully for many years with conventional treatment methods,
renders these ﬁndings remarkable. Remarkable is the fact, that in case of the long-term
studies underway for MD, patients show a stable response. This gives hope to a substan-
tial percentage of therapy–resistant psychiatric patients requiring new therapy approaches.
There are no fundamental ethic objections to its use in psychiatric disorders, but until sub-
stantial clinical data is available, mandatory standards are needed. DBS is a unique and very
promising method for the treatment of therapy–resistant psychiatric patients. The method
allows manipulating pathological neuronal networks in a very precise way.
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INTRODUCTION
PRINCIPLE, SAFETY, AND ADVANTAGES OF DBS
Different modalities of neuromodulation such as repetitive tran-
scranial magnetic stimulation (Schlaepfer et al., 2003; George,
2010), vagus nerve stimulation (Kosel and Schlaepfer, 2003;
Schlaepfer et al., 2008b), and magnetic seizure therapy (Lisanby
et al., 2001; Kayser et al., 2010) have been proposed and sys-
tematically studied in psychiatric different disorders (Schlaepfer
et al., 2010). Both clinically and scientiﬁcally the most promis-
ing method of neuromodulation might be deep brain stimulation
(DBS). DBS refers to the stereotaxic placement of unilateral or
bilateral electrodes connected to a permanently implanted neu-
rostimulator (Schlaepfer and Lieb, 2005b). The exact neurobio-
logical mechanisms by which DBS exerts effects on brain tissue are
not yet fully understood (Hardesty and Sackeim, 2007). Various
mechanisms have been discussed, on the neuronal level, excitatory
and inhibitory processes might play a role (McIntyre et al., 2004).
Most probably, DBS leads to a functional lesion of the surround-
ing tissue. Today, it is unknown which part of the neuron (e.g., cell
body, axon) is primarily modulated by DBS. Certainly, the stimu-
lation volume is not a ﬁxed area around the electrode and the effect
on neuronal tissue is variable. Stimulation parameters (frequency,
amplitude, pulse width, duration) also clearly have an impact on
the effect (Ranck, 1975). With commonly used parameters, a rel-
atively large volume of neural tissue is inﬂuenced (Kringelbach
et al., 2007).
Side effects in DBS are either related to the operation itself
(e.g., bleeding, local infections at the chest) or to the stimulation
(e.g., elevation of mood, anxiety, motor slowing). Fortunately, the
safety of the stereotactic operation technique has been extremely
improved in the last years with the help of neuroimaging. Bleeding
rate of DBS surgeries are between 0.2 and 5% (Kosel et al., 2007;
Kühn et al., 2007). On the other hand, DBS has many advantages
over traditional therapy methods: clinical effects can be achieved
without irreversible lesioning, stereotactic operation is the most
minimal neurosurgical method and electrodes can be completely
removed if necessary. Brain activity can be changed in a direct,
controlled manner. Furthermore, DBS offers the opportunity to
continuously adjust stimulation variables for each patient in order
to optimize therapy. The patient can turn off stimulation imme-
diately if side effects occur. DBS is the only neurosurgical method
that allows blinded studies for therapy control. In comparison to
antidepressant medication, nor side effects such as extrapyrami-
dal effects, weight gain, that substantially effect compliance and
patient’s quality of life, are reported. Also no long-time side effects
as in antidepressant treatments (Geddes et al., 2003; Furukawa
et al., 2007) have been reported. Nonetheless, DBS can be asso-
ciated with side effects due to stimulation that are transient and
can be counteracted by a change in stimulation parameters (see
Table 1). But until it has beenproven thatDBShas the same clinical
effect as pharmacotherapy, the latter together with psychotherapy
must be the ﬁrst treatment choice.
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Table 1 | Possible side effects of DBS in OCD or depression.
Negative effects of DBS Positive effects of DBS
For example, bleeding or local
infections at the chest caused
by the operation itself
Clinical effects can be achieved without
irreversible lesioning
For example, elevation of
mood, anxiety, motor slowing
caused by the stimulation
Electrodes can be completely removed
if necessary
Brain activity can be changed in a direct,
controlled manner
Opportunity to continuously adjust stimu-
lation variables for each patient individually
The patient can turn off stimulation
immediately if side effects occur
Allows blinded studies for therapy control
No extrapyramidal effects
No weight gain
No long-time side effects as in
antidepressant treatments are reported
Thus, DBS could become an exciting method in the treatment
of depression and obsessive–compulsive disorder (OCD) and
offers unique possibilities to gain more insight into the underlying
neurobiology of psychiatric disorders.
FIRST EFFICACY RESULTS IN OCD AND DEPRESSION
The main focus of studies on the underlying neurobiology of
major depression (MD) has focused on the description of bio-
logical differences between patients and healthy subjects such as
alterations of monoaminergic or endocrine systems. The relative
importance of the various biological changes has not been eluci-
dated; correlation with speciﬁc symptoms of the disease has rarely
been attempted. Psychotropic drugs work by altering neurochem-
istry to a large extent in widespread regions of the brain, many of
which may be unrelated to depression.
In contrast to some neurological disorders, the pathologi-
cal interplay of several brain regions contributes to the behav-
ioral, emotional, and cognitive symptoms of psychiatric disorders.
Metabolic studies suggest that different symptoms are mediated
by different brain regions (Berton and Nestler, 2006; Yurgelun-
Todd et al., 2007; Krishnan and Nestler, 2008) A convincing
network-model of depression integrating biochemical, electro-
physiological, imaging, and animal studies, has been described
by Mayberg (1997). According to this model, depression results
from a dysregulation of limbic–cortical connections: patholog-
ical changes in dorsal brain regions (including the dorsolateral
prefrontal cortex, inferior parietal cortex, and striatum) were asso-
ciated with cognitive symptoms (e.g., apathy, anhedonia, hope-
lessness, deﬁcits in attention, and executive function), changes in
ventral areas (hypothalamic–pituitary–adrenal axis, Insula, sub-
genual cingulate, and brainstem) contribute to the vegetative and
somatic aspects of depression (e.g., sleep disturbance, appetite,
endocrine dysregulation). This model underlines the role of the
rostral cingulate cortex in regulating the network (Mayberg, 1997).
The involvement of further regions in depression is discussed:
the hippocampus contributes to memory deﬁcits, the nucleus
accumbens was associated with anhedonia and lack of motiva-
tion, the amygdala plays a role in the processing of aversive stimuli
and avoidance (Berton and Nestler, 2006).
Obsessive–compulsive disorder is characterized by obsessions
(anxiety-provoking thoughts) and compulsions (repeated, time-
consuming behaviors; Stein, 2002). As in most psychiatric dis-
orders, a complex interplay of genetic factors, neurotransmitter
changes and psychosocial characteristics contribute to the devel-
opment of this disease. Changes in dopamine and serotonin have
been reported (Stein, 2002). Dysfunctions in a network connect-
ing the cortex and basal ganglia are supposed to underlie OCD.
Imaging data demonstrated changes in orbitofrontal cortex, ante-
rior cingulate cortex and caudate nucleus in OCD (Baxter, 1990).
Emerging evidence suggests that different alternations of the OCD
circuitry subserve different symptom subtypes (Kopell and Green-
berg, 2008). It has been hypothesized that an over activation of the
direct pathway of the cortico-striatal–pallidal–thalamic–cortical
loop leads to intrusive thoughts (Baxter et al., 2001).
These novel conceptualizations of both OCD and MD, brought
about mainly by advances in functional neuroimaging but also
electrophysiological andmolecular studies and their synthesis have
paved the road to hypothesis-guided studies on targeted reversible
neuromodulation with DBS in these disorders.
The subgenual cingulate cortex (Brodmann Area cg25) has
probably dysfunctional connections to the dorsal and ventral
compartments of the emotion regulation circuit in depression
(Mayberg, 1997). The subgenual cingulate cortex modulates neg-
ative mood states (Mayberg et al., 2005b). It has been involved
in acute sadness and in antidepressive treatment effects (Mayberg
et al., 2005a; Lozano et al., 2008). The rostral part of the cingu-
late cortex seems to play a key role in modulating the network of
depression (Mayberg, 1997).
Mayberg et al. (2005b) could demonstrate, that 2months after
surgery, 5/6 patients met the response criterion [baseline score in
the Hamilton Depression Rating Scale (HDRS) minus 50%], after
6months, four patients showed sustained response. Different neu-
ropsychological parameters that were impaired at baseline were
signiﬁcantly improved. A reduction in the pathological hyperac-
tivity in this region has also been demonstrated using positron
emission tomography (PET) in this study. During the blinded
sham stimulation phase (n = 1), the patient’s condition worsened
considerably. No adverse events due to stimulation were observed
(Mayberg et al., 2005b).
Malone et al. (2009) investigated the use of DBS at the ven-
tral capsule/ventral striatum (VC/VS). The VC/VS was targeted,
because former studies targeting theVC/VS inOCDpatients (Nut-
tin et al., 1999; Greenberg et al., 2006) showed improvement not
only for OCD symptoms but also for depressive symptoms. This
ﬁnding was supported by the fact that the VS has complex archi-
tecture and includes structures such as the bed nucleus of the
stria terminalis and the nucleus accumbens, which are regions
believed to be involved with stress-related and reward–motivation
components of depression (Forray and Gysling, 2004; Epstein
et al., 2006). Once stimulation was titrated to therapeutic ben-
eﬁt and the absence of adverse effects, patients received signiﬁcant
improvements in depressive symptoms measured by the HDRS.
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Responder rates of 40% at 6months (n = 15) and 53.3% at last
follow-up (mean last follow-up of 23.5 ± 14.9months) receiving
continuous DBS stimulation are referred. Remission rates were
reported 20% at 6months and 40% at last follow-up with the
HDRS. So the results of this study suggest that DBS of the VC/VS
could also provide beneﬁt in highly treatment-refractory patients
with depression. However, since the larger contacts of the VC/VS
leads have twice the surface area of standard leads used in other
DBS applications, more frequent battery replacements or rather
implanting recharging batteries should be considered (Malone
et al., 2009).
We selected the Nucleus Accumbens as target for DBS because
of its prominent role in the reward system. The Nucleus accum-
bens is known to act as motivational gateway between systems
involved in motor control and limbic systems in charge of emo-
tion processing; especially the ventral striatum is uniquely located
to modulate other regions of the brain (Schlaepfer et al., 2008a).
By targeting one site in a network of brain regions implicated in
processing of affective stimuli, it was possible to manipulate anhe-
donia in particular. It could be demonstrated that modulation
of this structure was associated with changes in the symptoms of
anhedonia and mood in three depressed patients. Stimulation cur-
rent correlated negatively with anhedonia ratings. Normalization
of brain metabolism in fronto-striatal networks as result of stimu-
lationwas also observed (Schlaepfer et al., 2008a). It is notable, that
no side effects due to stimulation were observed. Results from a
total of nine patients in this study show acute as well as long-term
antidepressant effects of DBS at this target have been published
recently, demonstrating a responder rate of 50% (Bewernick et al.,
2010).
The habenula has been proposed recently as target for DBS in
depression (Sartorius and Henn, 2007). Animal data and imaging
studies have shown, that this regions controls serotonergic ﬁbers
from the dorsal raphe nuclei and noradrenergic ﬁbers from the
locus coeruleus (Winter et al., 2011). The authors hypothesize
that over activation of the habenula is related to depression and
recently reported on the course of depression after DBS to the
habenula in a case report (Sartorius et al., 2010).
Another putative target site for MD has been proposed very
recently, the medial forebrain bundle (Coenen et al., 2011). Mag-
netic resonance diffusion tensor imaging (DTI) can visualize dis-
tinct functional circuits in the living human brain on the basis of
the anisotropy of the brain tissue. This technique has been applied
to an analysis of the different DBS sites for MD and lead to the
hypothesis-guided development of yet another site with hypothet-
ically greater efﬁcacy and even less unwanted effects. Pilot studies
assessing clinical efﬁcacy are underway.
Single-case studies in OCD patients with comorbid depres-
sion have shown antidepressant effects: bilateral stimulation of the
ventral nucleus caudatus in combination with Nucleus Accum-
bens for OCD led to remission of depression (HDRS_17< 7)
after 6month. No neuropsychological deterioration was reported
(Aouizerate et al., 2004).
It was supposed that dysregulation of the connection between
unspeciﬁc thalamic system and orbitofrontal cortex plays an
important role in the development of depression (Jiménez et al.,
2005). Therefore, bilateral stimulation of the lower thalamus
stem was performed one depressed patient and led to remission
(HDRS 42→ 10). The effect remained stable for 24months. Dur-
ing blinded discontinuation of stimulation, the patient’s condition
aggravated (Jiménez et al., 2005).
In OCD, there have been proposed different targets according
to the underlying pathological network. The orbitofrontal cor-
tex and the anterior cingulate cortex are part of the OCD circuit.
Unfortunately, these regions are very large and not well circum-
scribed in relation to this disease. Thus the size of cortex region
that needs to be modulated would be too large (Lipsman et al.,
2007). Inmost studies, the anterior limbof the internal capsulewas
the target for either unilateral or bilateral stimulation (Anderson
and Ahmed, 2003; Gabriels et al., 2003; Nuttin et al., 1999; Nuttin
et al., 2003; Sturm et al., 2003). All studies reported on promising
results ranging from response to complete remission. In terms of
side effects, some studies reported on induced,directly stimulation
related symptoms of hypomania which all ceased completely after
reduction of stimulation intensity.
TheNucleus thalamicus – zona incerta has been studied at three
patientswith Parkinson’s disease and comorbidOCD(Mallet et al.,
2002; Fontaine et al., 2004). Both studies reported considerable
amelioration of OCD symptoms. The subthalamic nucleus was
stimulated in a study (Malone et al., 2009), this group included
16 patients and received signiﬁcant lower symptoms of OCD. In a
recent OCD study targeting the subthalamic nucleus, OCD symp-
toms were signiﬁcantly reduced after the 3-months double-blind
stimulation phase compared to the double-blind sham stimulation
phase (Mallet et al., 2008). Both studies refer to possible associ-
ated risk of serious adverse events (Mallet et al., 2008; Malone
et al., 2009). The Nucleus Accumbens and Nucleus Caudatus were
target in one case study with comorbid depression (s above). This
patient achieved remission status (Aouizerate et al., 2004). Unilat-
eral stimulation of the NAcc in a well-designed, controlled study
lead to somewhat less impressive but signiﬁcant improvements
results in 10 patients (Huff et al., 2010). The stimulation of the
VC/VS led to a signiﬁcant improvement in 50% of the patients
(Greenberg et al., 2006). Side effects related to the stimulation
were transient hypomania and increased anxiety, which could be
counteracted by parameter change (Greenberg et al., 2006).
Recently results of bilateral DBS to the Nucleus Accumbens
in OCD with an open 8-month treatment phase, followed by
a double-blind crossover phase with randomly assigned 2-week
periods of active or sham stimulation, ending with an open 12-
month maintenance phase have been published (Denys et al.,
2010). Nine of the 16 patients were classiﬁed as responders, indi-
cating that bilateral stimulation of the nucleus accumbens may be
an effective and safe treatment in patients with highly refractory
OCD.
In summary, promising effects for different targets have been
demonstrated, but as worldwide sample sizes are small, it is too
early to select one favorable target if there is any. As OCD is a
heterogeneous disease, there might be different optimal targets for
different symptom clusters.
ETHICAL ISSUES
Introducing a new invasive therapeutic approach requires eval-
uation according to high ethical standards. The high mortality,
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low quality of life, and the social burden of inadequately treated
serious psychiatric illness favor the use of DBS for treatment-
resistant patients. The potential beneﬁt to the understanding of
pathological principles in mental disorders is evident (Schlaepfer
and Lieb, 2005a; Fuchs, 2006; Ford, 2007; Synofzik and Schlaepfer,
2008, 2010).
Fundamental ethical concerns are generally applicable to
all clinical interventions (e.g., pharmacotherapy, psychotherapy)
including DBS in neurological disorders. Foremost, are patients
able to give conformed consent? It has been demonstrated that
depressed patients show few impairments in decision-making
capacity related to clinical treatment research (Appelbaum et al.,
1999). Another concern is, how far human nature may ethically be
manipulated (Fuchs, 2006). Long-term effects of DBS cannot be
evaluated yet, but in comparison to pharmacotherapy, brain stim-
ulation is a more speciﬁc and reversible intervention. No harmful
effects are reported so far. More problematic is the danger of mis-
use, such as for mind control or for over-enhancement of normal
(healthy) cognitive function (“brain doping”; Fuchs, 2006; Ford,
2007). As clinical researchers in psychiatry, our aim is to help
patients to lead a normal life, including normal cognitive function
and personal autonomy.
More practical ethical concerns are the availability of alternative
treatment methods (e.g., pharmacotherapy, ECT, psychotherapy).
Taking to account that DBS is used only with treatment-resistant
patients, who have already shown no beneﬁt with other treatment
approaches currently available, the apparent reversibility of DBS
and its robust potential beneﬁts, as described by prior pilot stud-
ies, are strong ethical arguments for considering DBS treatment
for resistant psychiatric disorders (Synofzik and Schlaepfer, 2008,
2010).
However, there are also some notable risks with DBS, particu-
larly intracerebral bleeding and wound infection and its efﬁcacy
is not yet formally and extensively established in controlled trials.
Therefore, until the DBS treatment method is scientiﬁcally val-
idated; obligatory standards for patient inclusion and exclusion
criteria as well as the selection of targets are needed. Partly this
has been already described by Rabins et al. (2009), recommending
16 key points for guiding research and protecting the safety and
rights of research subjects, as well as Nuttin et al. (2002) advocat-
ing certain minimum requirements for using DBS in psychiatric
conditions. Whereas we question the suggestion of Nuttin et al.
(2002) to form a separate committee with only distant access to the
individual patient or no direct involvement to the study for review-
ing patient selection. It is our belief, that despite any committee
review – might it be as thorough and exhaustive as possible –
the clinical responsibility remains with the patient’s clinicians and
cannot be shared by review committees. So from our point of view
further research regarding obligatory standards in DBS is needed.
Another possible event to consider is the risk of selective pub-
lishing of results. This is by no means unique to DBS, but this area
is particularly vulnerable to bias because of an excessive reliance
on single-patient case reports (Schlaepfer and Fins, 2010). Until
cohort studies are routinely performed, the possibility will remain
that only positive results will be published at the expense of neg-
ative data that might also have important implications. Balanced
publishing of results is even more important taking to account,
that patients and public understanding of the risks and beneﬁts of
DBS is strongly shaped by media (Racine et al., 2007).
DISCUSSION
A substantial percentage of therapy–resistant psychiatric patients
require new therapy approaches. DBS offers the possibility to
manipulate pathological neuronal networks in a very precise way.
First studies showed very promising effects in depression and
OCD. There are no fundamental ethic objections to its use in psy-
chiatric disorders, but until substantial clinical data is available,
mandatory standards are needed for patient and target selection,
quality of research center, and study protocol. It is very important
to point out that in the actual stage of research; DBS for psychi-
atric diseases is clinical research on therapeutics. The beneﬁt of
this method has to be proven ﬁrst, until DBS will be available for
many patients. Before, much more information about the thera-
peutic effect, individual predictors of response, possible short and
long-time side effects, and neuroethical issues have to be gained.
Deep brain stimulation is a unique and very promising
method for the treatment of therapy–resistant psychiatric patients.
Nonetheless, the duration of the battery limits the choice of stim-
ulation parameters, increases the risk of infection, and raises treat-
ment costs. Rechargeable batteries are currently being introduced
to the ﬁeld. Actual technology allows mainly continuous stimu-
lation with little possibility for dynamic adjustment. A particular
advantage of DBS is, that it allows recording signals from the stim-
ulating electrodes (Cohen et al., 2009a,b,c) and combining these
data with functional neuroimaging in order to map the spatiotem-
poral unfolding of DBS-elicited whole brain activity will lead to a
much broader knowledge on functional and dysfunctional circuits
processing affective stimuli revealing fundamental mechanisms of
brain function.
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